Mark has over 20 years’ experience in knowledge intensive companies as CEO, consultant and VC investor. Mark has been CEO of two companies in the Life Sciences industry and two in optoelectronics, was interim executive for the University of Manchester leading graphene commercialisation, partner of a VC firm managing Europe’s largest university spin-out fund, lead consultant on European strategic and fundraising projects, guest lecturer at Manchester Business School, chair of governors of a state school and director of the Dovestone Learning Partnership. Altogether he has served on the board of directors with 15 companies, and, as an academic, has published around 50 peer-reviewed journal articles in optoelectronics and solid-state physics.
Mark is now CEO of Bioxydyn, leading business, strategic and operational development.
Geoff Parker is founder of Bioxydyn over a decade ago and its Scientific Director. He is also a Professor of Healthcare Engineering, Imaging and Enterprise at UCL and formerly a Professor of Biomedical Imaging at the University of Manchester. He has over 20 years MR imaging experience and has published over 200 peer-reviewed journal papers and is an acknowledged key opinion leader in the use of quantitative MRI in research and clinical trials. Geoff has helped define many of the quantitative MRI methods used in clinical trials today.
John Waterton is Professor of Translational Imaging at the University of Manchester. Formerly (until 2014) with AstraZeneca, he was Chief Scientist in Personalised Healthcare & Biomarkers, heading AZ's Translational Imaging organisation. Having co-authored of over 200 peer-reviewed publications using imaging biomarkers to support drug discovery and clinical development in a wide range of therapy areas including oncology, musculoskeletal, hepatology and respiratory, he is a world renowned expert in the field of imaging biomarkers.
Jo Naish is a physicist with academic and industrial experience in medical imaging research. In addition to her role at Bioxydyn, she is currently Lecturer in Magnetic Resonance Imaging at the University of Manchester where she conducts research into the development and clinical translation of quantitative MR imaging biomarkers in various clinical settings including cardiology, nephrology, respiratory medicine, oncology and obstetrics.
Richard (ACA) has held finance director positions in both large multinationals and SMEs, including Advanced Medical Solutions and Astra Zeneca. Richard’s expertise covers the full spectrum of services as a CFO.
Steve has considerable experience of working in and consulting to the pharmaceutical industry, providing strategic studies in new product development, business development and manufacturing across the healthcare industry. Steve has built three global consulting businesses from modest beginnings to multimillion-dollar enterprises at Coopers and Lybrand, IBM and PwC where he led the Pharmaceutical Team in Advisory Services.
Steve serves as Chairman and NED on a number of boards and is experienced in start-ups, fund raising and strategy. He is president of the NFP Pistoia Alliance and is a visiting professor at UCL.
We offer rewarding careers in areas including MR imaging physics, software development, data analysis and project management. If you are interested in joining our dynamic and growing team then please get in touch with us using the contact details below.
We are looking for a Software Engineer to join our expanding team at Bioxydyn. You will be part of the team developing and supporting our software platform VoxelFlow. You will have the opportunity to work on the development, implementation and testing of new image analysis tools in emerging fields of scientific interest.
This role is an excellent opportunity to learn rounded engineering skills in a biomedical environment and in a rigorous quality environment.